RSV-MVA-004

A Randomized, Double-blind, Phase III trial to assess clinical efficacy, safety and reactogenicity of the recombinant MVA-BN® RSV vaccine in adults 60-years of age and older

• Read More at bavarian-nordic.com
• Read More at globenewswire.com
• Older Adults are at high risk for severe RSV infection (cdc.gov)